Enter at least 3 characters
Home page > Media
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.   Parma Italy, Dublin...
Chiesi appoints Giuseppe Accogli as new Group CEO
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
Chiesi receives positive ESG rating from independent rating agency Cerved
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
New organisational order for the Chiesi Foundation
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Werelddag van de bossen en Chiesi
Chiesi opnieuw erkend als Top Employer
Kaia Health and Chiesi Group announce strategic partnership
Zorg Talks 18 november 2020: Wereld COPD-Dag
COPD-patiënt loopt risico bij uitstel van zorg door coronapandemie
Chiesi opnieuw ‘a Great Place to Work’
Chiesi tekent Green Deal Duurzame Zorg
We ACT Day 2020: Chiesi’s global event for a sustainable future return
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
Chiesi medewerkers over het werken bij Chiesi
"Wie weet is het arrivederci"
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification